American journal of veterinary research · 2026
Evaluation of dose-dependent effects of dapagliflozin on urinary glucose and plasma ketone bodies in healthy dogs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Umezawa Mutsuki, Orito Kensuke, Yoshimoto Ryo, Fujii Yoko
Аннотация
OBJECTIVE: To evaluate the dose-dependent effects of single dosing of dapagliflozin on pharmacodynamics, diuresis, and ketogenesis in dogs.
METHODS: This study included 5 healthy Beagles. A single dose of dapagliflozin (0.1, 0.3, or 1.0 mg/kg) or placebo was orally administered (randomized 14-day intervals) to each dog. Blood and urine samples were collected prior to administration and at 1, 2, 3, 4, 5, 6, 9, 12, and 24 hours after administration. A urinary catheter was placed from 0 to 6 hours after administration to monitor urine volume and collect samples; thereafter, urine was collected using a metabolic cage. Plasma ketone bodies, sodium, potassium, chloride, and glucose concentrations were measured. Urinary sodium, potassium, chloride, glucose, and urine volume were measured and compared among the treatment groups.
RESULTS: 24-hour urinary glucose excretion was significantly increased in the 0.3-mg/kg group compared with the 0.1-mg/kg group. However, no significant difference in 24-hour urinary glucose excretion was observed between the 0.3-and 1.0-mg/kg groups. Plasma ketone body concentration was significantly higher in the 1.0-mg/kg group compared with the placebo group at 4, 5, 6, 12, and 24 hours after administration. The 6-hour urine volume (mL/kg) was significantly higher in the 1.0-mg/kg group compared with the placebo group.
CONCLUSIONS: In healthy dogs, a single oral administration of dapagliflozin at 1.0 mg/kg induced both ketogenic and diuretic effects.
CLINICAL RELEVANCE: This study provides preliminary insight into dapagliflozin's effects in healthy dogs; further studies are needed to assess relevance in dogs with heart failure.
METHODS: This study included 5 healthy Beagles. A single dose of dapagliflozin (0.1, 0.3, or 1.0 mg/kg) or placebo was orally administered (randomized 14-day intervals) to each dog. Blood and urine samples were collected prior to administration and at 1, 2, 3, 4, 5, 6, 9, 12, and 24 hours after administration. A urinary catheter was placed from 0 to 6 hours after administration to monitor urine volume and collect samples; thereafter, urine was collected using a metabolic cage. Plasma ketone bodies, sodium, potassium, chloride, and glucose concentrations were measured. Urinary sodium, potassium, chloride, glucose, and urine volume were measured and compared among the treatment groups.
RESULTS: 24-hour urinary glucose excretion was significantly increased in the 0.3-mg/kg group compared with the 0.1-mg/kg group. However, no significant difference in 24-hour urinary glucose excretion was observed between the 0.3-and 1.0-mg/kg groups. Plasma ketone body concentration was significantly higher in the 1.0-mg/kg group compared with the placebo group at 4, 5, 6, 12, and 24 hours after administration. The 6-hour urine volume (mL/kg) was significantly higher in the 1.0-mg/kg group compared with the placebo group.
CONCLUSIONS: In healthy dogs, a single oral administration of dapagliflozin at 1.0 mg/kg induced both ketogenic and diuretic effects.
CLINICAL RELEVANCE: This study provides preliminary insight into dapagliflozin's effects in healthy dogs; further studies are needed to assess relevance in dogs with heart failure.